Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: A systematic review

European Urology

Volumn 67, Issue 5, 2015, Pages 876-888

  Casey, Rowan G ^a   Catto, James W F ^b   Cheng, Liang ^c   Cookson, Michael S ^d   Herr, Harry ^e   Shariat, Sharokh ^f   Witjes, J Alfred ^g   Black, Peter C ^h  

^a East Suffolk and North Essex Foundation Trust   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Bacillus Calmette Gu rin; Bladder; Fluorescent cystoscopy; Gemcitabine; Hyperthermia; Interferon ; Intravesical immunotherapy; Narrow band cystoscopy; Photodynamic diagnosis; Urothelial carcinoma in situ; Valrubicin

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CYTOKERATIN 20; GEMCITABINE; HERMES ANTIGEN; MITOMYCIN; PROTEIN P53; VALRUBICIN;

ARTICLE; BCG VACCINATION; BLADDER BIOPSY; BLADDER TUMOR; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; CONSERVATIVE TREATMENT; CYSTECTOMY; CYSTOSCOPY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SPECIFIC SURVIVAL; EVIDENCE BASED MEDICINE; FLUORESCENCE IN SITU HYBRIDIZATION; HIGH RISK POPULATION; HUMAN; HYPERTHERMIA; IMMUNOTHERAPY; LYMPH NODE DISSECTION; LYMPH VESSEL METASTASIS; MAINTENANCE THERAPY; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PELVIS LYMPH NODE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RECURRENCE FREE SURVIVAL; STANDARDIZATION; SURVIVAL RATE; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; TUMOR INVASION; URINE CYTOLOGY; UROTHELIAL CARCINOMA IN SITU;

EID: 84964238197     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.10.040     Document Type: Review

References (120)

1. S. Chavan, F. Bray, J. Lortet-Tieulent, M. Goodman, and A. Jemal International variations in bladder cancer incidence and mortality Eur Urol 66 2014 59 73
2. M. Babjuk, M. Burger, and R. Zigeuner EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013 Eur Urol 64 2013 639 653
3. S.P. Lerner, H. Liu, M.F. Wu, Y.K. Thomas, and J.A. Witjes Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder Urol Oncol 30 2012 285 289
4. I. Kausch, M. Sommerauer, and F. Montorsi Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies Eur Urol 57 2010 595 606
5. H.B. Grossman, A. Stenzl, and Y. Fradet Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy J Urol 188 2012 58 62
6. M. Burger, H.B. Grossman, and M. Droller Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data Eur Urol 64 2013 846 854
7. B. Geavlete, R. Multescu, D. Georgescu, F. Stanescu, M. Jecu, and P. Geavlete Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach Urology 79 2012 846 851
8. K. Tatsugami, K. Kuroiwa, and T. Kamoto Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer J Endourol 24 2010 1807 1811
9. K. Li, T. Lin, X. Fan, Y. Duan, and J. Huang Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and meta-analysis Int J Urol 20 2013 602 609
10. P. Shen, J. Yang, W. Wei, Y. Li, D. Li, and H. Zeng Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis BJU Int 110 2012 E209 E215
11. J.A. Witjes Management of BCG failures in superficial bladder cancer: a review Eur Urol 49 2006 790 797
12. B.P. Schrier, M.P. Hollander, B.W. van Rhijn, L.A. Kiemeney, and J.A. Witjes Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy Eur Urol 45 2004 292 296
13. S. van den Bosch, and J.A. Witjes Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review Eur Urol 60 2011 493 500
14. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
15. Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine - levels of evidence (March 2009). Centre for Evidence-based Medicine Web site. http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/1998/.
16. R.E. Orozco, R. Vander Zwaag, and W.M. Murphy The pagetoid variant of urothelial carcinoma in situ Hum Pathol 24 1993 1199 1202
17. N. Nese, R. Gupta, M.H. Bui, and M.B. Amin Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis J Natl Compr Canc Netw 7 2009 48 57
18. A. Lopez-Beltran, and R.E. Jimenez Flat urothelial carcinoma in situ of the bladder with glandular differentiation Hum Pathol 42 2011 1653 1659
19. D. Lamm, H. Herr, and G. Jakse Updated concepts and treatment of carcinoma in situ Urol Oncol 4 1998 130 138
20. G.A.F. Sauter, M.B. Amin, and C. Busch Non-invasive urothelial neoplasias: WHO classification of non invasive papillary urothelial tumors 2004 IARC Press Lyon, France
21. D.C. Chade, S.F. Shariat, and A. Adamy Clinical outcome of primary versus secondary bladder carcinoma in situ J Urol 184 2010 464 469
22. Z. Kirkali, T. Chan, and M. Manoharan Bladder cancer: epidemiology, staging and grading, and diagnosis Urology 66 2005 4 34
23. W.M. Murphy, K. Takezawa, and N.A. Maruniak Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care J Urol 168 2002 968 972
24. J.A. Witjes, P.M. Moonen, and A.G. van der Heijden Review pathology in a diagnostic bladder cancer trial: effect of patient risk category Urology 67 2006 751 755
25. F.E. Sharkey, and M.F. Sarosdy The significance of central pathology review in clinical studies of transitional cell carcinoma in situ J Urol 157 1997 68 70 discussion 71
26. M.C. Lee, H.S. Levin, and J.S. Jones The role of pathology review of transurethral bladder tumor resection specimens in the modern era J Urol 183 2010 921 927
27. A. van der Meijden, W. Oosterlinck, M. Brausi, K.H. Kurth, R. Sylvester, and C. de Balincourt Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee Eur Urol 35 1999 267 271
28. F. May, U. Treiber, R. Hartung, and H. Schwaibold Significance of random bladder biopsies in superficial bladder cancer Eur Urol 44 2003 47 50
29. A.P. van der Meijden, R. Sylvester, and W. Oosterlinck EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ Eur Urol. 48 2005 363 371
30. D.C. Utz, K.A. Hanash, and G.M. Farrow The plight of the patient with carcinoma in situ of the bladder J Urol 103 1970 160 164
31. H. Wolf, F. Melsen, S.E. Pedersen, and K.T. Nielsen Natural history of carcinoma in situ of the urinary bladder Scand J Urol Nephrol Suppl 157 1994 147 151
32. H.W. Herr, C.M. Pinsky, W.F. Whitmore Jr., H.F. Oettgen, and M.R. Melamed Effect of intravesical bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder Cancer 51 1983 1323 1326
33. M.S. Cookson, H.W. Herr, Z.F. Zhang, S. Soloway, P.C. Sogani, and W.R. Fair The treated natural history of high risk superficial bladder cancer: 15-year outcome J Urol 158 1997 62 67
34. F. Jacobsen, C. Moller-Nielsen, and S. Mommsen Flat intra-epithelial carcinoma in situ of the urinary bladder Scand J Urol Nephrol 19 1985 253 255
35. I. Fukui, M. Yokokawa, and H. Sekine Carcinoma in situ of the urinary bladder. Effect of associated neoplastic lesions on clinical course and treatment Cancer 59 1987 164 173
36. M.R. Melamed, N.G. Voutsa, and H. Grabstald Natural history and clinical behavior of in situ carcinoma of the human urinary bladder Cancer 17 1964 1533 1545
37. G.M. Farrow, D.C. Utz, C.C. Rife, and L.F. Greene Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder Cancer Res 37 1977 2794 2798
38. A.F. Althausen, G.R. Prout Jr., and J.J. Daly Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ J Urol 116 1976 575 580
39. G.R. Prout Jr., P.P. Griffin, and J.J. Daly The outcome of conservative treatment of carcinoma in situ of the bladder J Urol 138 1987 766 770
40. P.R. Riddle, G.D. Chisholm, P.A. Trott, and R.C. Pugh Flat carcinoma in situ of bladder Br J Urol 47 1975 829 833
41. E. Solsona, I. Iborra, and J.V. Ricos Biological behavior of untreated bladder carcinoma in situ [in Spanish] Arch Esp Urol 43 1990 643 645
42. K.H. Kurth, P.F. Schellhammer, and E. Okajima Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra Int J Urol 2 Suppl 2 1995 8 22
43. C. Bolenz, A.M. West, N. Ortiz, W. Kabbani, and Y. Lotan Urinary cytology for the detection of urothelial carcinoma of the bladder-a flawed adjunct to cystoscopy? Urol Oncol 31 2013 366 371
44. A.M. Kamat, P.K. Hegarty, and J.R. Gee ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers Eur Urol 63 2013 4 15
45. M. Rink, M. Babjuk, and J.W. Catto Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature Eur Urol 64 2013 624 638
46. J. Bergman, R.C. Reznichek, and J. Rajfer Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings BJU Int 101 2008 26 29
47. H.M. Fritsche, M. Burger, and W. Dietmaier Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder Am J Clin Pathol 134 2010 597 603
48. M.F. Sarosdy, P. Schellhammer, and G. Bokinsky Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer J Urol 168 2002 1950 1954
49. A.M. Kamat, and S. Porten Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer Eur Urol 65 2014 267 269
50. D.L. Lamm, B.A. Blumenstein, and J.D. Crissman Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study J Urol 163 2000 1124 1129
51. H.W. Herr Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy J Urol 174 2005 2134 2137
52. P.U. Malmström, R.J. Sylvester, and D.E. Crawford An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247 256
53. D.C. Chade, S.F. Shariat, and G. Godoy Clinical outcomes of primary bladder carcinoma in situ in a contemporary series J Urol 184 2010 74 80
54. G. Jakse, R. Hall, and A. Bono Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861 Eur Urol 40 2001 144 150
55. T.R. Griffiths, M. Charlton, D.E. Neal, and P.H. Powell Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance J Urol 167 2002 2408 2412
56. R.J. Sylvester, A.P.M. van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
57. T.M. de Reijke, K.H. Kurth, and R.J. Sylvester Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group phase III trial (30906) J Urol 173 2005 405 409
58. J. Oddens, M. Brausi, and R. Sylvester Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance Eur Urol 63 2013 462 472
59. A.G. van der Heijden, L.A. Kiemeney, and O.N. Gofrit Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder Eur Urol 46 2004 65 71 discussion 72
60. J.A. Witjes, K. Hendricksen, O. Gofrit, O. Risi, and O. Nativ Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party World J Urol 27 2009 319 324
61. S.M. Di Stasi, A. Giannantoni, and R.L. Stephen Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study J Urol 170 2003 777 782
62. S.M. Di Stasi, A. Giannantoni, and A. Giurioli Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial Lancet Oncol 7 2006 43 51
63. W. Oosterlinck, Z. Kirkali, and R. Sylvester Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC Genito-Urinary Group randomized phase 2 trial (30993) Eur Urol 59 2011 438 446
64. E. Kaasinen, H. Wijkstrom, and P.U. Malmstrom Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study Eur Urol 43 2003 637 645
65. R. Jarvinen, E. Kaasinen, E. Rintala, and T.F. Group Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up Scand J Urol Nephrol 46 2012 411 417
66. D.R. Yates, M.A. Brausi, and J.W.F. Catto Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer Eur Urol 62 2012 1088 1096
67. V.W. Merz, D. Marth, R. Kraft, D.K. Ackermann, E.J. Zingg, and U.E. Studer Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder Br J Urol 75 1995 180 184
68. G. Giannarini, F.D. Birkhauser, F. Recker, G.N. Thalmann, and U.E. Studer Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra Eur Urol 65 2014 825 831
69. B.L. Gallagher, F.N. Joudi, J.L. Maymi, and M.A. O'Donnell Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy Urology 71 2008 297 301
70. F.N. Joudi, and M.A. O'Donnell Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures Curr Opin Urol 14 2004 271 275
71. F.N. Joudi, B.J. Smith, M.A. O'Donnell National BCG-Interferon Phase 2 Investigator Group Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer Urol Oncol 24 2006 344 348
72. H.M. Rosevear, A.J. Lightfoot, and K.K. Birusingh Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ J Urol 186 2011 817 823
73. T.T. Bui, and P.F. Schellhammer Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response Urology 49 1997 687 690 discussion 690-1
74. P.R. Bretton, H.W. Herr, and M. Kimmel The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin J Urol 143 1990 710 712 discussion 712-3
75. C.R. Lockyer, J.E. Sedgwick, and D.A. Gillatt Beware the BCG failures: a review of one institution's results Eur Urol 42 2002 542 546
76. G. Steinberg, R. Bahnson, S. Brosman, R. Middleton, Z. Wajsman, and M. Wehle Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group J Urol 163 2000 761 767
77. C.P. Dinney, R.E. Greenberg, and G.D. Steinberg Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin Urol Oncol 31 2013 1635 1642
78. G. Di Lorenzo, S. Perdona, and R. Damiano Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial Cancer 116 2010 1893 1900
79. G. Dalbagni, P. Russo, and B. Bochner Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder J Clin Oncol 24 2006 2729 2734
80. P. Gontero, C. Fiorito, M. Oderda, G. Pappagallo, and M. Brausi Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: what does an aborted trial tell us? Urol Oncol 31 2013 671 675
81. E.C. Skinner, B. Goldman, and W.A. Sakr SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin J Urol 190 2013 1200 1204
82. L. Barlow, J.M. McKiernan, and M.C. Benson Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy J Urol 189 2013 834 839
83. A. Morales, K. Phadke, and G. Steinhoff Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed J Urol 181 2009 1040 1045
84. E. Watanabe, H. Matsuyama, and K. Matsuda Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder Cancer Immunol Immunother 52 2003 481 486
85. F. Saint, J.J. Patard, and P. Maille Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer J Urol 167 2002 364 367
86. P.A. Videira, F.M. Calais, and M. Correia Efficacy of bacille Calmette-Guérin immunotherapy predicted by expression of antigen-presenting molecules and chemokines Urology 74 2009 944 950
87. M.P. Simons, M.A. O'Donnell, and T.S. Griffith Role of neutrophils in BCG immunotherapy for bladder cancer Urol Oncol 26 2008 341 345
88. A.R. Zlotta, J.C. Noel, and I. Fayt Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guérin intravesical therapy J Urol 161 1999 792 798
89. R. Nunez-Nateras, E.P. Castle, and C.A. Protheroe Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder Urol Oncol 32 2014 45 e23-30
90. F. Thomas, A.P. Noon, N. Rubin, J. Goepel, and J.W. Catto Comparative outcomes of primary, recurrent and progressive high-risk non-muscle invasive bladder cancer Eur Urol 63 2013 145 154
91. R. De Jager, P. Guinan, and D. Lamm Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials Urology 38 1991 507 513
92. J.M. Hassan, M.S. Cookson, J.A. Smith Jr., D.L. Johnson, and S.S. Chang Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy J Urol 172 2004 882 884
93. L. Cheng, J.C. Cheville, and R.M. Neumann Survival of patients with carcinoma in situ of the urinary bladder Cancer 85 1999 2469 2474
94. H.W. Herr, and P.C. Sogani Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166 2001 1296 1299
95. F. Saint, L. Salomon, and R. Quintela Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist? Analysis of a quarter century of literature Eur Urol 43 2003 351 360 discussion 360-1
96. D. Tilki, O. Reich, and R.S. Svatek Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients J Urol 183 2010 1757 1763
97. S.F. Shariat, G.S. Palapattu, and G.E. Amiel Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy Urology 68 2006 538 542
98. G.J. Huang, P.H. Kim, D.G. Skinner, and J.P. Stein Outcomes of patients with clinical CIS-only disease treated with radical cystectomy World J Urol 27 2009 21 25
99. P. Zehnder, F. Moltzahn, and S. Daneshmand Outcome in patients with exclusive carcinoma in situ (CIS) after radical cystectomy BJU Int 113 2014 65 69
100. J.P. Stein, G. Lieskovsky, and R. Cote Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 2001 666 675
101. H.M. Bruins, E.C. Skinner, and R.P. Dorin Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: results from a prospective lymph node mapping study Urol Oncol 32 2014 24 e13-9
102. C.L. Amling, J.B. Thrasher, H.A. Frazier, R.K. Dodge, J.E. Robertson, and D.F. Paulson Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder J Urol 151 1994 31 35 discussion 35-6
103. S. Madersbacher, W. Hochreiter, and F. Burkhard Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy J Clin Oncol 21 2003 690 696
104. R.E. Hautmann, J.E. Gschwend, R.C. de Petriconi, M. Kron, and B.G. Volkmer Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era J Urol 176 2006 486 492 discussion 491-2
105. S.F. Shariat, P.I. Karakiewicz, and G.S. Palapattu Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium J Urol 176 2006 2414 2422 discussion 2422
106. M.A. Ghoneim, M. Abdel-Latif, and M. el-Mekresh Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later J Urol 180 2008 121 127
107. F.A. Yafi, A.G. Aprikian, and J.L. Chin Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience BJU Int 108 2011 539 545
108. H. Isbarn, P.I. Karakiewicz, and S.F. Shariat Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer J Urol 182 2009 459 465 discussion 465
109. J. Palou, J. Baniel, and L. Klotz Urothelial carcinoma of the prostate Urology 69 2007 50 61
110. H. Zincke, D.C. Utz, and G.M. Farrow Review of Mayo Clinic experience with carcinoma in situ Urology 26 1985 39 46
111. R.G. Nixon, S.S. Chang, B.J. Lafleur, J.J. Smith, and M.S. Cookson Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder J Urol 167 2002 502 505
112. M.P. Revelo, M.S. Cookson, S.S. Chang, M.F. Shook, J.A. Smith Jr., and S.B. Shappell Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery J Urol 171 2004 646 651
113. F. Liedberg, H. Anderson, and M. Blackberg Prospective study of transitional cell carcinoma in the prostatic urethra and prostate in the cystoprostatectomy specimen. Incidence, characteristics and preoperative detection Scand J Urol Nephrol 41 2007 290 296
114. N. Sakamoto, M. Tsuneyoshi, S. Naito, and J. Kumazawa An adequate sampling of the prostate to identify prostatic involvement by urothelial carcinoma in bladder cancer patients J Urol 149 1993 318 321
115. S.S. Shen, S.P. Lerner, B. Muezzinoglu, L.D. Truong, G. Amiel, and T.M. Wheeler Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance Hum Pathol 37 2006 726 734
116. S. Gudjonsson, M. Blackberg, and G. Chebil The value of bladder mapping and prostatic urethra biopsies for detection of carcinoma in situ (CIS) BJU Int 110 2012 E41 E45
117. K.I. Wishnow, and J.Y. Ro Importance of early treatment of transitional cell carcinoma of prostatic ducts Urology 32 1988 11 12
118. E. Mukamel, M. Konichezky, D. Engelstein, S. Cytron, A. Abramovici, and C. Servadio Clinical and pathological findings in prostates following intravesical bacillus Calmette-Guerin instillations J Urol 144 1990 1399 1400
119. O.N. Gofrit, D. Pode, G. Pizov, K.C. Zorn, R. Katz, and A. Shapiro Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Guérin immunotherapy? BJU Int 103 2009 905 908
120. H.W. Herr, and S.M. Donat Prostatic tumor relapse in patients with superficial bladder tumors: 15-year outcome J Urol 161 1999 1854 1857